VistaGen Therapeutics (VTGN)
0.29
+0.01 (3.57%)
Upcoming Events
Latest Headlines
Form 8-K Vistagen Therapeutics, For: Aug 06
August 6, 2026 4:22 PM - SEC Filing
Vistagen reports Phase 2 repeat dose results for fasedienol in SAD
August 6, 2026 8:31 AM - StreetInsider
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
August 6, 2026 8:30 AM - StreetInsider
Form 8-K Vistagen Therapeutics, For: Aug 04
August 5, 2026 4:05 PM - SEC Filing
SRX Global acquires stake in Vistagen Therapeutics
August 4, 2026 5:00 AM - StreetInsider
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
August 4, 2026 5:00 AM - StreetInsider
Form DEFA14A Vistagen Therapeutics,
July 31, 2026 4:11 PM - SEC Filing
Form DEF 14A Vistagen Therapeutics, For: Jul 31
July 31, 2026 4:11 PM - SEC Filing
Form 4 Vistagen Therapeutics, For: Jul 29 Filed by: Williamson Douglas J
July 31, 2026 8:56 AM - SEC Filing
Form 3 Vistagen Therapeutics, For: Jul 29 Filed by: Williamson Douglas J
July 31, 2026 8:53 AM - SEC Filing
Form 8-K Vistagen Therapeutics, For: Jul 29
July 31, 2026 8:49 AM - SEC Filing
Vistagen names neuroscience veteran Douglas Williamson to its board
July 31, 2026 8:30 AM - StreetInsider
Vistagen Appoints Douglas J. Williamson to its Board of Directors
July 31, 2026 8:30 AM - StreetInsider
Form 4 Vistagen Therapeutics, For: Jun 30 Filed by: Adler Reid G.
July 2, 2026 4:34 PM - SEC Filing
Form 4 Vistagen Therapeutics, For: Jun 30 Filed by: Tressler Nick B.
July 2, 2026 4:18 PM - SEC Filing
Form 4 Vistagen Therapeutics, For: Jun 30 Filed by: Singh Shawn
July 2, 2026 4:17 PM - SEC Filing
Form 8-K Vistagen Therapeutics, For: Jun 30
June 30, 2026 8:29 AM - SEC Filing
Vistagen's fasedienol misses Phase 3 endpoints in anxiety trial
June 30, 2026 8:01 AM - StreetInsider
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
June 30, 2026 8:00 AM - BizWire
VistaGen Therapeutics (VTGN) Halted, News Pending
June 30, 2026 7:58 AM - StreetInsider
Form 8-K Vistagen Therapeutics, For: Jun 16
June 17, 2026 5:14 PM - SEC Filing
Form 10-K Vistagen Therapeutics, For: Mar 31
June 15, 2026 4:50 PM - SEC Filing
Form 8-K Vistagen Therapeutics, For: Jun 15
June 15, 2026 4:35 PM - SEC Filing
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
June 15, 2026 4:30 PM - BizWire
Form 8-K Vistagen Therapeutics, For: Jun 09
June 9, 2026 5:05 PM - SEC Filing
Vistagen meets ICH safety exposure standards for fasedienol trials
June 9, 2026 8:31 AM - StreetInsider
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
June 9, 2026 8:30 AM - BizWire
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
May 27, 2026 8:30 AM - BizWire
Form 4 Vistagen Therapeutics, For: May 18 Filed by: Angelov Angel S
May 19, 2026 4:52 PM - SEC Filing
Form 3 Vistagen Therapeutics, For: May 18 Filed by: Angelov Angel S
May 19, 2026 4:52 PM - SEC Filing
Form 8-K Vistagen Therapeutics, For: May 18
May 19, 2026 4:30 PM - SEC Filing
Vistagen names Angel Angelov as chief medical officer
May 19, 2026 8:30 AM - StreetInsider
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
May 19, 2026 8:30 AM - BizWire
Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: TCG Crossover GP II, LLC
May 15, 2026 4:33 PM - SEC Filing
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 14, 2026 8:30 AM - BizWire
Form 8-K Vistagen Therapeutics, For: May 12
May 12, 2026 7:45 AM - SEC Filing
Vistagen reports preliminary positive safety data from fasedienol trial
May 12, 2026 7:30 AM - StreetInsider
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
May 12, 2026 7:30 AM - BizWire
Full Article List
